MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
QUICK SEARCH:   [advanced]


     

Molecular Pharmacology Fast Forward
First published on November 5, 2007; DOI: 10.1124/mol.107.041178

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.041178v1
73/2/490    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liao, Z.
Right arrow Articles by Pommier, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liao, Z.
Right arrow Articles by Pommier, Y.


Received for publication August 23, 2007.
Revised November 2, 2007.
Accepted for publication November 2, 2007.

Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan

Zhiyong Liao 1, Robert W. Robey 2, Josee Guirouilh-Barbat 1, Kenneth K. W. To 2, Orsolya Polgar 2, Susan E. Bates 2, Yves Pommier 1*

1 LMP, CCR, NCI, NIH 2 MOB, CCR, NCI, NIH

* Address correspondence to: E-mail: pommier{at}nih.gov

Abstract

Homocamptothecins (hCPTs) are a novel class of topoisomerase I (Top1) inhibitors with enhanced chemical stability compared to the currently used camptothecin (CPT) analogues, irinotecan and topotecan. The hCPT derivative, diflomotecan (BN80915), is currently in clinical trials. We established two resistant human glioblastoma cell lines, SF295/hCPT50 and SF295/BN50 by stepwise exposure of the parental SF295 line to increasing concentrations of hCPT and BN80915, respectively. The two resistant cell lines were 15- to 22-fold resistant to hCPT and BN80915 as well as 7- to 27-fold cross resistant to other Top1 inhibitors, including CPT, topotecan, and the indenoisoquinolines MJ-III-65 (NSC 706744) and NSC 724998, but sensitive to the topoisomerase II inhibitors mitoxantrone and etoposide. Neither of the resistant cell lines displayed any detectable expression of the three major drug transporters Pgp, MRP1 or ABCG2 as assessed by immunoblot or flow cytometry. Reduced expression of Top1 protein occurred at the transcriptional level in both of the resistant cell lines, consistent with the reduction of Top1 enzyme level as the major contribution to the resistance phenotype in SF295/hCPT50 and SF295/BN50 cells. Treatment of the resistant cell lines with the histone deacetylase inhibitor depsipeptide or the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine alone or concomitantly did not result in re-expression of Top1. Our studies suggest that selection for resistance to hCPT or BN80915 is primarily related to reduced Top1 expression at the transcriptional level, resulting in reduced enzyme levels.


Key words: MDR/p-Glycoprotein, Resistance, Topoisomerases


This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
T. D. Pfister, W. C. Reinhold, K. Agama, S. Gupta, S. A. Khin, R. J. Kinders, R. E. Parchment, J. E. Tomaszewski, J. H. Doroshow, and Y. Pommier
Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity
Mol. Cancer Ther., July 1, 2009; 8(7): 1878 - 1884.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics